Novel use of the extract of processed Panax genus plant and saponin compound isolated therefrom

A pharmaceutical composition comprising the extract of Panax genus plant obtained by the steps essentially comprising acid or heat treating or their combination thereof the plant material belonged to Panax genus and subsequent fermentation treating with lactic-acid bacteria or intestinal bacteria, as an active ingredient in an amount effective to treat or prevent human or mammal gastro-intestinal diseases caused by abnormal proliferation of Helicobacter pylori, together with a pharmaceutically acceptable carrier.

A pharmaceutical compositions comprising saponin compounds selected from the group consisting of panaxytriol, panaxydol, panaxynol, ginsenoside Rc, Rb1, 20(S)-ginsenoside Rg3, 20(R)-ginsenoside Rg3, 20(S)-ginsenoside Rh2, 20(R)-ginsenoside Rh2, 20(R)-protopanaxadiol, 20(S)-protopanaxadiol, 20(S)-ginsenoside Rh1, 20(S)-protopanaxatriol and the mixture thereof, as an active ingredient in an amount effective to treat or prevent human or mammal gastro-intestinal diseases caused by abnormal proliferation of Helicobacter pylori, together with a pharmaceutically acceptable carrier.

A method for treating or preventing gastro-intestinal disease in a mammal comprising administrating to said mammal an effective amount of the extract wherein the ratio of ginsenoside (Rk2+Rh3+protopanaxadiol+20-dehydroprotopanaxadiol) to (Rg3+Rg5+Rk1) of above 0.1, together with a pharmaceutically acceptable carrier thereof.

A method for treating or preventing gastro-intestinal disease in a mammal comprising administrating to said mammal an effective amount of Panax genus plant or the extract thereof obtained by the steps essentially comprising acid or heat treating or their combination thereof the plant material belonged to Panx genus and subsequent fermentation treating with lactic-acid bacteria or intestinal bacteria, together with a pharmaceutically acceptable carrier thereof.

A method for treating or preventing gastro-intestinal disease in a mammal comprising administrating to said mammal an effective amount of a compound selected from the group consisting of panaxytriol, panaxydol, panaxynol, ginsenoside Rc, Rb1, 20(S)-ginsenoside Rg3, 20(R)-ginsenoside Rg3, 20(S)-ginsenoside Rh2, 20(R)-ginsenoside Rh2, 20(R)-protopanaxadiol, 20(S)-protopanaxadiol, 20(S)-ginsenoside Rh1, 20(S)-protopanaxatriol and the mixture thereof, together with a pharmaceutically acceptable carrier thereof.